NASDAQ : SANA
Sana Biotechnology, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.57 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 769.36M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 769.36M |
| Enterprise Value | 689.81M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 299.36M |
| Shares Outstanding | 299.36M |
| Shares Change (YoY) | +17.07% |
| Shares Change (QoQ) | +6.79% |
| Owned by Insiders (%) | 6.30% |
| Owned by Institutions (%) | 47.62% |
| Float | 190.89M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.98 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.38 |
| Quick Ratio | 1.30 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -152.87% |
| Return on Assets (ROA) | -29.16% |
| Return on Invested Capital (ROIC) | -52.15% |
| Return on Capital Employed (ROCE) | -60.13% |
| Weighted Average Cost of Capital (WACC) | 15.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.49M |
| Employee Count | 142 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.30 |
| 52-Week Price Change | -52.14% |
| 50-Day Moving Average | 3.04 |
| 200-Day Moving Average | 3.39 |
| Relative Strength Index (RSI) | 46.16 |
| Average Volume (20 Days) | 3,137,882 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 40.85M |
| Short Previous Month | 38.73M |
| Short % of Shares Out | 13.64% |
| Short % of Float | 21.40% |
| Short Ratio (days to cover) | 10.22 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -185.06M |
| Pretax Income | -211.82M |
| Net Income | -211.82M |
| EBITDA | -174.19M |
| EBIT | -185.06M |
| Earnings Per Share (EPS) | -$0.76 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 160.49M |
| Total Debt | 80.94M |
| Net Cash | 79.55M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 154.57M |
| Book Value Per Share | 0.52 |
| Working Capital | 46.88M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -132.24M |
| Capital Expenditures | -2.82M |
| Depreciation & Amortization | 10.87M |
| Net Borrowing | -360,000 |
| Free Cash Flow | -135.06M |
| FCF Per Share | -$0.45 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -17.07% |
| Shareholder Yield | n/a |
| Earnings Yield | -29.71% |
| FCF Yield | -17.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.43 |
| Price Target Difference | 228.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |